GDC-0834 is a compound researched and developed for medical applications, particularly in treating immune-related and inflammatory diseases. It has potential in inhibiting Bruton's tyrosine kinase (BTK), which plays a key role in B-cell signaling in the immune system. Inhibiting BTK may help reduce inflammation and symptoms of autoimmune diseases such as rheumatoid arthritis. Additionally, GDC-0834 is being studied to evaluate its efficacy in treating certain cancers related to BTK function. However, research is still in the experimental stage, and further studies are needed to confirm safety and efficacy in humans.